Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.
Several other equities analysts also recently issued reports on the stock. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $9.00 to $1.25 in a report on Wednesday. HC Wainwright cut Leap Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday.
Check Out Our Latest Report on Leap Therapeutics
Leap Therapeutics Price Performance
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP increased its stake in shares of Leap Therapeutics by 268.2% in the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after acquiring an additional 58,094 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its stake in Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after purchasing an additional 37,067 shares during the period. Simplify Asset Management Inc. boosted its holdings in Leap Therapeutics by 67.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after purchasing an additional 425,626 shares during the last quarter. Valence8 US LP acquired a new stake in shares of Leap Therapeutics during the 3rd quarter worth approximately $48,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Leap Therapeutics during the 3rd quarter worth approximately $65,000. 30.46% of the stock is owned by hedge funds and other institutional investors.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Recommended Stories
- Five stocks we like better than Leap Therapeutics
- Most active stocks: Dollar volume vs share volume
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Growth Stocks: What They Are, What They Are Not
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.